On September 13, 2021 ProMIS Neurosciences, Inc. (TSX: PMN) (OTCQB: ARFXF), a biotechnology company focused on the discovery and development of antibody therapeutics targeting toxic oligomers implicated in the development of neurodegenerative diseases, reported its participation in H.C. Wainwright & Co., 23rd Annual Investment Conference being held virtually September 13-15 2021 (Press release, ProMIS Neurosciences, SEP 13, 2021, https://promisneurosciences.com/news/promis-neurosciences-to-participate-in-h-c-wainwright-co-23rd-annual-investment-conference/ [SID1234587609]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

ProMIS Executive Chairman, Eugene Williams, will provide an update on the company with special focus on PMN310, ProMIS’ lead antibody for Alzheimer’s disease (AD), as well as an overview of the Company’s unique, proprietary technology platform and ProMIS’ expanding portfolio of antibody therapeutic candidates targeting in addition to AD, amyotrophic lateral sclerosis (ALS), Parkinson’s disease (PD) and beyond. A narrated version of the slide deck presented at the conference is available on the ProMIS website by clicking on the following link: